ct-1

CT-1 is a DNA minor groove ligand and causes p53-dependent breast cancer cell apoptosis.

CT1-3 is a potent anti-cancer agent. CT1-3 regulates the JNK/Bcl-2/Bax/XIAP pathway, which induces mitochondria-mediated apoptosis. CT1-3 regulates the E-cadherin/Snail axis to inhibit epithelial mesenchymal transition (EMT) potentials in human cancer cells (HCCs) and suppresses tumourigenesis. CT1-3 has anti-tumour effects in mouse models and does not show significant hepatotoxicity or nephrotoxicity.

CT-179 is a potent and selective inhibitor of oligodendrocyte transcription factor 2 (OLIG2), reduces tumor cell proliferation and induces apoptosis, and enhances efficacy when used in combination with radiotherapy and other agents, showing potential in the treatment of medulloblastoma and glioblastoma.

3-hydroxy-3-(methoxycarbonyl)-2-[(1E)-oct-1-en-1-yl]pentanedioic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

2-hydroxy-1-[(1E)-oct-1-en-1-yl]propane-1,2,3-tricarboxylic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(oct-1-en-3-yloxy)oxane-3,4,5-triol is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

CT-133 is a selective and potent antagonist of the CRTH2 Receptor, with a Ki value of 2.2 nM, and exhibits a Ki greater than 3800 nM for the DP1 receptor. It inhibits PGD2-induced neutrophil migration and significantly reduces lung inflammation and improves lung function impairment in a mouse model of acute lung injury (ALI) induced by cigarette smoke. Additionally, CT-133 effectively suppresses the overexpression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and the chemokine (KC) while reversing the suppression of the anti-inflammatory factor IL-10. CT-133 is useful for ALI research.

8-Iodooct-1-yne is a PROTAC linker utilized in the synthesis of PROTAC molecules.

NCT-10b is a selective inhibitor of HDAC6.

ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.

ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Trametinib (GSK1120212) is a MEK inhibitor that inhibits MEK1 and MEK2 (IC50=0.7/0.9 nM) with ATP non-competitive and oral activity. Trametinib activates autophagy and induces apoptosis.

(-)-Epigallocatechin Gallate (EGCG) is a phenolic antioxidant polyphenol flavonoid found in plants such as green and black tea, which inhibits telomerase and DNA methyltransferase, blocks the activation of EGF receptors and HER-2 receptors, inhibits cellular oxidation, and prevents free radical damage to cells.

Cyclophosphamide is an alkylating agent type of anti-tumor drug, and its main target is DNA. Cyclophosphamide inhibits the proliferation of tumor cells by undergoing alkylation reactions with DNA, interfering with the replication and transcription processes of DNA.

Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.

Corticosterone (Kendall's compound B) is an adrenocortical steroid with salocorticoid and glucocorticoid activity that is orally active. Corticosterone is involved in the regulation of energy, immune responses, and stress responses in the body.

Fludarabine (Fludarabinum) is a fluorinated purine analog, an inhibitor of nucleic acid synthesis and an inhibitor of STAT1 activation. Fludarabine has antitumor activity and can be used for the treatment of leukemia and lymphoma.

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.

Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.

Defactinib (VS-6063) is a second-generation inhibitor of FAK that inhibits FAK phosphorylation at the Tyr397 site. Defactinib has potential antitumor activity.

ABT-737 is a BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (EC50=30.3 nM/78.7 nM/197.8 nM). ABT-737 exhibits antitumor activity and anti-aging activity.

MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis.

Alisertib (MLN 8237) is a specific Aurora A inhibitor (IC50: 1.2 nM). The selectivity of Alisertib(MLN 8237) is >200-fold higher for Aurora A than Aurora B.